Showing 2 posts of 2 posts found.
The US Food and Drug Administration (FDA) announced it has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for Cresemba …
The FDA has given the OK to Astellas and Basilea for their new treatment in adults with a rare but …
Envirogen secures place on NHS Scotland reverse osmosis framework
Europa Biosite enters Czech market with acquisition of diagnostics distributor
Qureight paper argues for fibrosis extent as imaging biomarker in lung disease trials
START and Rome cancer institute partner to expand early-phase trial access in Italy
AbbVie expands Oxford R&D facility with new £120m UK research commitment